Related Experiment Video
Updated: Jan 25, 2026

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
Published on: July 14, 2021
PI3Kα Pathway Inhibition With Doxorubicin Treatment Results in Distinct Biventricular Atrophy and Remodeling With
Brent A McLean1,2, Vaibhav B Patel2,3, Pavel Zhabyeyev2,3
11 Department of Physiology University of Alberta Edmonton Canada.
Abstract:
Background Cancer therapies inhibiting PI 3Kα (phosphoinositide 3-kinase-α)-dependent growth factor signaling, including trastuzumab inhibition of HER 2 (Human Epidermal Growth Factor Receptor 2), can cause adverse effects on the heart. Direct inhibition of PI 3Kα is now in clinical trials, but the effects of PI 3Kα pathway inhibition on heart atrophy, remodeling, and function in the context of cancer therapy are not well understood. Method and Results Pharmacological PI 3Kα inhibition and heart-specific genetic deletion of p110α, the catalytic subunit of PI 3Kα, was characterized in conjunction with anthracycline (doxorubicin) treatment in female murine models. Biventricular changes in heart morphological characteristics and function were analyzed, with molecular characterization of signaling pathways. Both PI 3Kα inhibition and anthracycline therapy promoted heart atrophy and a combined effect of distinct right ventricular dilation, dysfunction, and cardiomyocyte remodeling in the absence of pulmonary arterial hypertension. Congruent findings of right ventricular dilation and dysfunction were seen with pharmacological and genetic suppression of PI 3Kα signaling when combined with doxorubicin treatment. Increased p38 mitogen-activated protein kinase activation was mechanistically linked to heart atrophy and correlated with right ventricular dysfunction in explanted failing human hearts. Conclusions PI 3Kα pathway inhibition promotes heart atrophy in mice. The right ventricle is specifically at risk for dilation and dysfunction in the setting of PI 3K inhibition in conjunction with chemotherapy. Inhibition of p38 mitogen-activated protein kinase is a proposed therapeutic target to minimize this mode of cardiotoxicity.
Insights
Cancer therapies targeting PI 3Kα (phosphoinositide 3-kinase-α) can harm the heart. This study found PI 3Kα inhibition combined with chemotherapy specifically risks right ventricular dilation and dysfunction.
Area of Science:
- Cardiology
- Oncology
- Molecular Biology
Background:
- Cancer therapies targeting PI 3Kα (phosphoinositide 3-kinase-α) signaling can cause cardiac adverse effects.
- The impact of PI 3Kα pathway inhibition on heart health during cancer treatment remains unclear.
Purpose of the Study:
- To investigate the effects of PI 3Kα pathway inhibition on heart atrophy, remodeling, and function.
- To determine the specific cardiac risks associated with combined PI 3Kα inhibition and chemotherapy.
Main Methods:
- Utilized pharmacological PI 3Kα inhibition and genetic deletion of p110α in murine models.
- Administered anthracycline (doxorubicin) chemotherapy concurrently.
- Analyzed biventricular morphology, function, and molecular signaling pathways.
Main Results:
- Both PI 3Kα inhibition and doxorubicin promoted heart atrophy.
- Combined therapy led to right ventricular dilation, dysfunction, and cardiomyocyte remodeling without pulmonary hypertension.
- Increased p38 mitogen-activated protein kinase activation was linked to heart atrophy and right ventricular dysfunction.
Conclusions:
- PI 3Kα pathway inhibition contributes to heart atrophy.
- The right ventricle is particularly vulnerable to dilation and dysfunction when PI 3Kα inhibition is combined with chemotherapy.
- Inhibiting p38 mitogen-activated protein kinase may mitigate this cardiotoxicity.
More Related Videos
Related Concept Videos
Feedback Inhibition
Nucleosome Remodeling
Nucleosome remodeling complex
Eukaryotic cells have specialized enzymes called ATP-dependent nucleosome remodeling enzymes. These enzymes...
Bone Remodeling
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Osteoclasts in Bone Remodeling
Enzyme Inhibition

